Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm ...
Key Takeaways The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely ...
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
The number of bird flu cases in Central Massachusetts is relatively low, compared to a swath of the state that runs from ...
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...
The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...
Moderna (NASDAQ: MRNA) shares fell over 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...